SPRYCEL
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jun 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
5/8 — Partial
Priority Review
SPRYCEL by Bristol Myers Squibb is dasatinib, at nanomolar concentrations, inhibits the following kinases: bcr-abl, src family (src, lck, yes, fyn), c-kit, epha2, and pdgfrβ. Approved for older with • ph+ cml in chronic phase, • newly diagnosed adults with philadelphia chromosome-positive (ph+) chronic myeloid leukemia (cml) in chronic phase. First approved in 2006.
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPRYCEL (dasatinib) is an oral small-molecule tyrosine kinase inhibitor that targets BCR-ABL and SRC family kinases, approved for treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. It was designed to overcome imatinib resistance through inhibition of multiple BCR-ABL conformations and alternative signaling pathways. The drug represents a foundational second-generation TKI in the CML treatment landscape.
$0.51BPart D
LOE ApproachingDeclining
As LOE approaches, the brand team is likely consolidating to core maintenance activities with reduced headcount and marketing spend, signaling a shift toward operational efficiency and transition planning.
Mechanism of Action
Dasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro , dasatinib was active in leukemic cell lines…
Indications (2)
Worked on SPRYCEL at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.